Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Pharmaceutical Design
  4. Fast Track Articles
  5. Fast Track Article
image of Mucosal Melanoma: An Overview of Recent Therapies

Abstract

Mucosal Melanoma (MM) is an aggressive disease that is distinct from cutaneous melanoma risk in risk factors, prognosis, and treatment. Surgical treatment is currently the treatment of choice for localized disease; however, the recurrence rate is common. For advanced or metastatic disease, immunotherapy with PD-1 inhibitors and anti-CTLA is generally first-line treatment, however the overall responses to immunotherapy in MM are often lower and less robust when compared to that observed in cutaneous melanoma. Adoptive-TIL therapy have shown great promise. Other advances, particularly through the exploration of novel and combination therapies is a step forward and a hope to improve outcomes in patients with mucosal melanoma. In this review, we summarize current treatment options for MM, and we updated future clinical trials available for this population of patients.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cpd/10.2174/0113816128340751241220045149
2025-01-02
2025-01-30

  • From This Site

    /content/journals/cpd/10.2174/0113816128340751241220045149
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Chang A.E. Karnell L.H. Menck H.R. The National Cancer Data Base report on cutaneous and noncutaneous melanoma. Cancer 1998 83 8 1664 1678 10.1002/(SICI)1097‑0142(19981015)83:8<1664::AID‑CNCR23>3.0.CO;2‑G 9781962
    [Google Scholar]
  2. McLaughlin CC Wu X-C Jemal A Martin HJ Roche LM Chen VW Incidence of noncutaneous melanomas in the U.S 2005. Cancer 2005 103 5 1000 1007
    [Google Scholar]
  3. Kuk D. Shoushtari A.N. Barker C.A. Panageas K.S. Munhoz R.R. Momtaz P. Prognosis of mucosal, uveal, acral, nonacral cutaneous, and unknown primary melanoma from the time of first metastasis. Oncologist 2016 21 848 854
    [Google Scholar]
  4. Lian B. Cui C.L. Zhou L. Song X. Zhang X.S. Wu D. Si L. Chi Z.H. Sheng X.N. Mao L.L. Wang X. Tang B.X. Yan X.Q. Kong Y. Dai J. Li S.M. Bai X. Zheng N. Balch C.M. Guo J. The natural history and patterns of metastases from mucosal melanoma: An analysis of 706 prospectively-followed patients. Ann. Oncol. 2017 28 4 868 873 10.1093/annonc/mdw694 28039178
    [Google Scholar]
  5. Boer F.L. Ho V.K.Y. Louwman M.W.J. Schrader A.M.R. Zuur C.L. Blank C.U. van Poelgeest M.I.E. Kapiteijn E.H.W. Trends in incidence and survival of 1496 patients with mucosal melanoma in The Netherlands (1990–2019). Cancers 2023 15 5 1541 10.3390/cancers15051541 36900332
    [Google Scholar]
  6. Chi Z. Li S. Sheng X. Si L. Cui C. Han M. Guo J. Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: A study of 522 consecutive cases. BMC Cancer 2011 11 1 85 10.1186/1471‑2407‑11‑85 21349197
    [Google Scholar]
  7. Sutherland C.M. Chmiel J.S. Henson D.E. Winchester D.P. Patient characteristics, methods of diagnosis, and treatment of mucous membrane melanoma in the United States of America. J. Am. Coll. Surg. 1994 179 5 561 566 7952459
    [Google Scholar]
  8. Chen S.W. Li M.H. Liu J.L. Chen J.T. Wang J. Li H. Li X.Y. Zhang Y. Song M. Lu J.X. Chen W.K. Treatment outcomes of mucosal melanoma of the head and neck: Analysis of 190 cases from a single institution. Laryngoscope Investig. Otolaryngol. 2023 8 3 686 692 10.1002/lio2.1072 37342113
    [Google Scholar]
  9. Clavero-Rovira L. Gómez-Tomás Á. Bassas-Freixas P. Bodet D. Ferrer B. Hernández-Losa J. Muñoz-Couselo E. Pérez-Benavente A. García-Patos V. Ferrándiz-Pulido C. Mucosal melanoma clinical management and prognostic implications: A retrospective cohort study. Cancers 2024 16 1 227 10.3390/cancers16010227 38201654
    [Google Scholar]
  10. Wolchok J.D. Chiarion-Sileni V. Gonzalez R. Grob J.J. Rutkowski P. Lao C.D. Cowey C.L. Schadendorf D. Wagstaff J. Dummer R. Ferrucci P.F. Smylie M. Butler M.O. Hill A. Márquez-Rodas I. Haanen J.B.A.G. Guidoboni M. Maio M. Schöffski P. Carlino M.S. Lebbé C. McArthur G. Ascierto P.A. Daniels G.A. Long G.V. Bas T. Ritchings C. Larkin J. Hodi F.S. Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma. J. Clin. Oncol. 2022 40 2 127 137 10.1200/JCO.21.02229 34818112
    [Google Scholar]
  11. Knight A. Karapetyan L. Kirkwood J.M. Immunotherapy in Melanoma. Cancers 2023 15 4 1106 10.3390/cancers15041106 36831449
    [Google Scholar]
  12. Bedikian A.Y. Millward M. Pehamberger H. Conry R. Gore M. Trefzer U. Pavlick A.C. DeConti R. Hersh E.M. Hersey P. Kirkwood J.M. Haluska F.G. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J. Clin. Oncol. 2006 24 29 4738 4745 10.1200/JCO.2006.06.0483 16966688
    [Google Scholar]
  13. Tyrrell H. Payne M. Combatting mucosal melanoma: Recent advances and future perspectives. Melanoma Manag. 2018 5 3 MMT11 10.2217/mmt‑2018‑0003 30459941
    [Google Scholar]
  14. Carvajal R.D. Spencer S.A. Lydiatt W. Mucosal melanoma: A clinically and biologically unique disease entity. J. Natl. Compr. Canc. Netw. 2012 10 3 345 356 10.6004/jnccn.2012.0034 22393195
    [Google Scholar]
  15. Manolidis S. Donald P.J. Malignant mucosal melanoma of the head and neck. Cancer 1997 80 8 1373 1386 10.1002/(SICI)1097‑0142(19971015)80:8<1373::AID‑CNCR3>3.0.CO;2‑G 9338460
    [Google Scholar]
  16. Lee S.P. Shimizu K.T. Tran L.M. Juillard G. Calcaterra T.C. Mucosal melanoma of the head and neck: The impact of local control on survival. Laryngoscope 1994 104 2 121 126 10.1288/00005537‑199402000‑00001 8302112
    [Google Scholar]
  17. Nilsson P.J. Ragnarsson-Olding B.K. Importance of clear resection margins in anorectal malignant melanoma. Br. J. Surg. 2010 97 1 98 103 10.1002/bjs.6784 20013935
    [Google Scholar]
  18. Meleti M. Leemans C.R. de Bree R. Vescovi P. Sesenna E. van der Waal I. Head and neck mucosal melanoma: Experience with 42 patients, with emphasis on the role of postoperative radiotherapy. Head Neck 2008 30 12 1543 1551 10.1002/hed.20901 18704960
    [Google Scholar]
  19. Patel S.G. Prasad M.L. Escrig M. Singh B. Shaha A.R. Kraus D.H. Boyle J.O. Huvos A.G. Busam K. Shah J.P. Primary mucosal malignant melanoma of the head and neck. Head Neck 2002 24 3 247 257 10.1002/hed.10019 11891956
    [Google Scholar]
  20. Bachar G. Loh K.S. O’Sullivan B. Goldstein D. Wood S. Brown D. Irish J. Mucosal melanomas of the head and neck: experience of the Princess Margaret Hospital. 2008 30 10 1325 1331 10.1002/hed.20878 18704964
    [Google Scholar]
  21. Hieken T.J. Kane J.M. Wong S.L. Role of Completion Lymph Node Dissection for Sentinel Lymph Node-Positive Melanoma 2019 26 1028 1034
    [Google Scholar]
  22. Broman K.K. Hughes T. Dossett L. Sun J. Kirichenko D. Carr M.J. Sharma A. Bartlett E.K. Nijhuis A.A.G. Thompson J.F. Hieken T.J. Kottschade L. Downs J. Gyorki D.E. Stahlie E. van Akkooi A. Ollila D.W. Frank J. Song Y. Karakousis G. Moncrieff M. Nobes J. Vetto J. Han D. Farma J.M. Deneve J.L. Fleming M.D. Perez M.C. Lowe M.C. Olofsson Bagge R. Mattsson J. Lee A.Y. Berman R.S. Chai H. Kroon H.M. Teras J. Teras R.M. Farrow N.E. Beasley G. Hui J.Y.C. Been L. Kruijff S. Kim Y. Naqvi S.M.H. Sarnaik A.A. Sondak V.K. Zager J.S. Active surveillance of patients who have sentinel node positive melanoma: an international, multi‐institution evaluation of adoption and early outcomes after the multicenter selective lymphadenectomy trial II (MSLT‐2). Cancer 2021 127 13 2251 2261 10.1002/cncr.33483 33826754
    [Google Scholar]
  23. Lian B. Li Z. Wu N. Li M. Chen X. Zheng H. Gao M. Wang D. Sheng X. Tian H. Si L. Chi Z. Wang X. Lai Y. Sun T. Zhang Q. Kong Y. Long G.V. Guo J. Cui C. Phase II clinical trial of neoadjuvant anti-PD-1 (toripalimab) combined with axitinib in resectable mucosal melanoma. Ann. Oncol. 2024 35 2 211 220 10.1016/j.annonc.2023.10.793 37956739
    [Google Scholar]
  24. Ho J. Mattei J. Tetzlaff M. Williams M.D. Davies M.A. Diab A. Oliva I.C.G. McQuade J. Patel S.P. Tawbi H. Wong M.K. Fisher S.B. Hanna E. Keung E.Z. Ross M. Weiser R. Su S.Y. Frumovitz M. Meyer L.A. Jazaeri A. Pettaway C.A. Guadagnolo B.A. Bishop A.J. Mitra D. Farooqi A. Bassett R. Faria S. Nagarajan P. Amaria R.N. Neoadjuvant checkpoint inhibitor immunotherapy for resectable mucosal melanoma. Front. Oncol. 2022 12 1001150 10.3389/fonc.2022.1001150 36324592
    [Google Scholar]
  25. Lian B. Si L. Cui C. Chi Z. Sheng X. Mao L. Li S. Kong Y. Tang B. Guo J. Phase II randomized trial comparing high-dose IFN-α2b with temozolomide plus cisplatin as systemic adjuvant therapy for resected mucosal melanoma. Clin. Cancer Res. 2013 19 16 4488 4498 10.1158/1078‑0432.CCR‑13‑0739 23833309
    [Google Scholar]
  26. Lian B. Si L. Chi Z.H. Sheng X.N. Kong Y. Wang X. Tian H. Li K. Mao L.L. Bai X. Tang B.X. Yan X.Q. Li S.M. Zhou L. Dai J. Tang X.W. Ran F.W. Yao S. Guo J. Cui C.L. Toripalimab (anti-PD-1) versus high- dose interferon-α2b as adjuvant therapy in resected mucosal melanoma: A phase II randomized trial. Ann. Oncol. 2022 33 10 1061 1070 10.1016/j.annonc.2022.07.002 35842199
    [Google Scholar]
  27. Kottschade L.A. Pond G.R. Olszanski A.J. Zakharia Y. Domingo-Musibay E. Hauke R.J. Curti B.D. Schober S. Milhem M.M. Block M.S. Hieken T. McWilliams R.R. SALVO. Clin. Cancer Res. 2023 29 12 2220 2225 10.1158/1078‑0432.CCR‑22‑3207 37000165
    [Google Scholar]
  28. Lian B. Tian H. Si L. Chi Z. Sheng X. Wang X. Temozolomide plus cisplatin versus toripalimab (anti-PD-1) as adjuvant therapy in resected mucosal melanoma. 2023 41 9508 9508
    [Google Scholar]
  29. Postow M.A. Hamid O. Carvajal R.D. Mucosal melanoma: Pathogenesis, clinical behavior, and management. Curr. Oncol. Rep. 2012 14 5 441 448 10.1007/s11912‑012‑0244‑x 22661391
    [Google Scholar]
  30. Nenclares P. Ap Dafydd D. Bagwan I. Begg D. Kerawala C. King E. Lingley K. Paleri V. Paterson G. Payne M. Silva P. Steven N. Turnbull N. Yip K. Harrington K.J. Head and neck mucosal melanoma: The United Kingdom national guidelines. Eur. J. Cancer 2020 138 11 18 10.1016/j.ejca.2020.07.017 32829104
    [Google Scholar]
  31. https://www.uptodate.com/contents/locoregional-mucosal-melanoma-epidemiology-clinical-diagnosis-and-treatment?topicRef=138441&source=see_link#H32364415
  32. Krengli M Masini L Kaanders JHAM Maingon P Oei SB Zouhair A Radiotherapy in the treatment of mucosal melanoma of the upper aerodigestive tract: Analysis of 74 cases. A rare cancer network study. Int J Radiat Oncol Biol Phys. 2006 65 3 751 759 2006
    [Google Scholar]
  33. Jacques S.K. McKeown J. Grover P. Johnson D.B. Zaremba A. Dimitriou F. Weiser R. Farid M. Namikawa K. Sullivan R.J. Rutkowski P. Lebbe C. Hamid O. Zager J.S. Michielin O. Neyns B. Nakamura Y. Robert C. Mehnert J. Ascierto P.A. Bhave P. Park B. Zimmer L. Mangana J. Mooradian M. Placzke J. Allayous C. Glitza Oliva I.C. Mehmi I. Depalo D. Wicky A. Schwarze J.K. Roy S. Boatwright C. Vanella V. Long G.V. Menzies A.M. Lo S.N. Carlino M.S. Outcomes of patients with resected stage III/IV acral or mucosal melanoma, treated with adjuvant anti-PD-1 based therapy. Eur. J. Cancer 2024 199 113563 10.1016/j.ejca.2024.113563 38278007
    [Google Scholar]
  34. Dubus M. Charles J. Leccia M.T. Mouret S. Trabelsi S. Long-term response of vulvar mucosal melanoma treated with neoadjuvant nivolumab. JAAD Case Rep. 2023 38 14 16 10.1016/j.jdcr.2023.05.037 37600735
    [Google Scholar]
  35. Postow M.A. Luke J.J. Bluth M.J. Ramaiya N. Panageas K.S. Lawrence D.P. Ibrahim N. Flaherty K.T. Sullivan R.J. Ott P.A. Callahan M.K. Harding J.J. D’Angelo S.P. Dickson M.A. Schwartz G.K. Chapman P.B. Gnjatic S. Wolchok J.D. Hodi F.S. Carvajal R.D. Ipilimumab for patients with advanced mucosal melanoma. Oncologist 2013 18 6 726 732 10.1634/theoncologist.2012‑0464 23716015
    [Google Scholar]
  36. Alexander M. Mellor J.D. McArthur G. Kee D. Ipilimumab in pretreated patients with unresectable or metastatic cutaneous, uveal and mucosal melanoma. Med. J. Aust. 2014 201 1 49 53 10.5694/mja13.10448 24999899
    [Google Scholar]
  37. Zimmer L. Eigentler T.K. Kiecker F. Simon J. Utikal J. Mohr P. Berking C. Kämpgen E. Dippel E. Stadler R. Hauschild A. Fluck M. Terheyden P. Rompel R. Loquai C. Assi Z. Garbe C. Schadendorf D. Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma. J. Transl. Med. 2015 13 1 351 10.1186/s12967‑015‑0716‑5 26541511
    [Google Scholar]
  38. Del Vecchio M. Di Guardo L. Ascierto P.A. Grimaldi A.M. Sileni V.C. Pigozzo J. Ferraresi V. Nuzzo C. Rinaldi G. Testori A. Ferrucci P.F. Marchetti P. De Galitiis F. Queirolo P. Tornari E. Marconcini R. Calabrò L. Maio M. Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma. Eur. J. Cancer 2014 50 1 121 127 10.1016/j.ejca.2013.09.007 24100024
    [Google Scholar]
  39. Shoushtari A.N. Munhoz R.R. Kuk D. Ott P.A. Johnson D.B. Tsai K.K. Rapisuwon S. Eroglu Z. Sullivan R.J. Luke J.J. Gangadhar T.C. Salama A.K.S. Clark V. Burias C. Puzanov I. Atkins M.B. Algazi A.P. Ribas A. Wolchok J.D. Postow M.A. The efficacy of anti‐PD‐1 agents in acral and mucosal melanoma. Cancer 2016 122 21 3354 3362 10.1002/cncr.30259 27533633
    [Google Scholar]
  40. Schaefer T. Satzger I. Gutzmer R. Clinics, prognosis and new therapeutic options in patients with mucosal melanoma. Medicine 2017 96 1 e5753 10.1097/MD.0000000000005753 28072717
    [Google Scholar]
  41. Takahashi A. Tsutsumida A. Namikawa K. Nakamura Y. Muto I. Yamazaki N. The efficacy of nivolumab for unresectable metastatic mucosal melanoma. 2016 27 vi383
    [Google Scholar]
  42. Hamid O. Robert C. Ribas A. Hodi F.S. Walpole E. Daud A. Arance A.S. Brown E. Hoeller C. Mortier L. Schachter J. Long J. Ebbinghaus S. Ibrahim N. Butler M. Antitumour activity of pembrolizumab in advanced mucosal melanoma: A post-hoc analysis of KEYNOTE-001, 002, 006. Br. J. Cancer 2018 119 6 670 674 10.1038/s41416‑018‑0207‑6 30202085
    [Google Scholar]
  43. Moya-Plana A. Herrera Gómez R.G. Rossoni C. Dercle L. Ammari S. Girault I. Roy S. Scoazec J.Y. Vagner S. Janot F. Eggermont A.M.M. Robert C. Evaluation of the efficacy of immunotherapy for non-resectable mucosal melanoma. Cancer Immunol. Immunother. 2019 68 7 1171 1178 10.1007/s00262‑019‑02351‑7 31172258
    [Google Scholar]
  44. D’Angelo S.P. Larkin J. Sosman J.A. Lebbé C. Brady B. Neyns B. Schmidt H. Hassel J.C. Hodi F.S. Lorigan P. Savage K.J. Miller W.H. Jr Mohr P. Marquez-Rodas I. Charles J. Kaatz M. Sznol M. Weber J.S. Shoushtari A.N. Ruisi M. Jiang J. Wolchok J.D. Efficacy and safety of nivolumab alone or in combination with ipilimumab in patients with mucosal melanoma: A pooled analysis. J. Clin. Oncol. 2017 35 2 226 235 10.1200/JCO.2016.67.9258 28056206
    [Google Scholar]
  45. Shoushtari A.N. Wagstaff J. Ascierto P.A. Butler M.O. Lao C.D. Marquez-Rodas I. CheckMate 067: Long-term outcomes in patients with mucosal melanoma. 2020 38 10019 10019
    [Google Scholar]
  46. Davies H. Bignell G.R. Cox C. Stephens P. Edkins S. Clegg S. Teague J. Woffendin H. Garnett M.J. Bottomley W. Davis N. Dicks E. Ewing R. Floyd Y. Gray K. Hall S. Hawes R. Hughes J. Kosmidou V. Menzies A. Mould C. Parker A. Stevens C. Watt S. Hooper S. Wilson R. Jayatilake H. Gusterson B.A. Cooper C. Shipley J. Hargrave D. Pritchard-Jones K. Maitland N. Chenevix-Trench G. Riggins G.J. Bigner D.D. Palmieri G. Cossu A. Flanagan A. Nicholson A. Ho J.W.C. Leung S.Y. Yuen S.T. Weber B.L. Seigler H.F. Darrow T.L. Paterson H. Marais R. Marshall C.J. Wooster R. Stratton M.R. Futreal P.A. Mutations of the BRAF gene in human cancer. Nature 2002 417 6892 949 954 10.1038/nature00766 12068308
    [Google Scholar]
  47. Curtin J.A. Busam K. Pinkel D. Bastian B.C. Somatic activation of KIT in distinct subtypes of melanoma. J. Clin. Oncol. 2006 24 26 4340 4346 10.1200/JCO.2006.06.2984 16908931
    [Google Scholar]
  48. Beadling C. Jacobson-Dunlop E. Hodi F.S. Le C. Warrick A. Patterson J. Town A. Harlow A. Cruz F. III Azar S. Rubin B.P. Muller S. West R. Heinrich M.C. Corless C.L. KIT gene mutations and copy number in melanoma subtypes. Clin. Cancer Res. 2008 14 21 6821 6828 10.1158/1078‑0432.CCR‑08‑0575 18980976
    [Google Scholar]
  49. Bai X. Mao L.L. Chi Z.H. Sheng X.N. Cui C.L. Kong Y. Dai J. Wang X. Li S.M. Tang B.X. Lian B. Zhou L. Yan X.Q. Guo J. Si L. BRAF inhibitors: Efficacious and tolerable in BRAF-mutant acral and mucosal melanoma. Neoplasma 2017 64 4 626 632 10.4149/neo_2017_419 28485171
    [Google Scholar]
  50. Buchbinder E.I. Weirather J.L. Manos M. Quattrochi B.J. Sholl L.M. Brennick R.C. Bowling P. Bailey N. Magarace L. Ott P.A. Haq R. Izar B. Giobbie-Hurder A. Hodi F.S. Characterization of genetics in patients with mucosal melanoma treated with immune checkpoint blockade. Cancer Med. 2021 10 8 2627 2635 10.1002/cam4.3789 33724703
    [Google Scholar]
  51. Satzger I. Schaefer T. Kuettler U. Broecker V. Voelker B. Ostertag H. Kapp A. Gutzmer R. Analysis of c-KIT expression and KIT gene mutation in human mucosal melanomas. Br. J. Cancer 2008 99 12 2065 2069 10.1038/sj.bjc.6604791 19018266
    [Google Scholar]
  52. Steeb T. Wessely A. Petzold A. Kohl C. Erdmann M. Berking C. Heppt M.V. c-Kit inhibitors for unresectable or metastatic mucosal, acral or chronically sun-damaged melanoma: A systematic review and one-arm meta-analysis. Eur. J. Cancer 2021 157 348 357 10.1016/j.ejca.2021.08.015 34562816
    [Google Scholar]
  53. Iqbal N. Iqbal N. Imatinib: A breakthrough of targeted therapy in cancer. Chemother. Res. Pract. 2014 2014 1 9 10.1155/2014/357027 24963404
    [Google Scholar]
  54. Meng D. Carvajal R.D. KIT as an oncogenic driver in melanoma: An update on clinical development. Am. J. Clin. Dermatol. 2019 20 3 315 323 10.1007/s40257‑018‑0414‑1 30707374
    [Google Scholar]
  55. Woodman S.E. Trent J.C. Stemke-Hale K. Lazar A.J. Pricl S. Pavan G.M. Fermeglia M. Gopal Y.N.V. Yang D. Podoloff D.A. Ivan D. Kim K.B. Papadopoulos N. Hwu P. Mills G.B. Davies M.A. Activity of dasatinib against L576P KIT mutant melanoma: Molecular, cellular, and clinical correlates. Mol. Cancer Ther. 2009 8 8 2079 2085 10.1158/1535‑7163.MCT‑09‑0459 19671763
    [Google Scholar]
  56. Kim K.B. Sanguino A.M. Hodges C. Papadopoulos N.E. Eton O. Camacho L.H. Broemeling L.D. Johnson M.M. Ballo M.T. Ross M.I. Gershenwald J.E. Lee J.E. Mansfield P.F. Prieto V.G. Bedikian A.Y. Biochemotherapy in patients with metastatic anorectal mucosal melanoma. Cancer 2004 100 7 1478 1483 10.1002/cncr.20113 15042682
    [Google Scholar]
  57. Bartell H.L. Bedikian A.Y. Papadopoulos N.E. Dett T.K. Ballo M.T. Myers J.N. Hwu P. Kim K.B. Biochemotherapy in patients with advanced head and neck mucosal melanoma. Head Neck 2008 30 12 1592 1598 10.1002/hed.20910 18798304
    [Google Scholar]
  58. Li S. Wu X. Yan X. Zhou L. Chi Z. Si L. Cui C. Tang B. Mao L. Lian B. Wang X. Bai X. Dai J. Kong Y. Tang X. Feng H. Yao S. Flaherty K.T. Guo J. Sheng X. Toripalimab plus axitinib in patients with metastatic mucosal melanoma: 3-year survival update and biomarker analysis. J. Immunother. Cancer 2022 10 2 e004036 10.1136/jitc‑2021‑004036 35193932
    [Google Scholar]
  59. Shibue T. Weinberg R.A. EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. Nat. Rev. Clin. Oncol. 2017 14 10 611 629 10.1038/nrclinonc.2017.44 28397828
    [Google Scholar]
  60. Easwaran H. Tsai H.C. Baylin S.B. Cancer epigenetics: Tumor heterogeneity, plasticity of stem-like states, and drug resistance. Mol. Cell 2014 54 5 716 727 10.1016/j.molcel.2014.05.015 24905005
    [Google Scholar]
  61. Burrell R.A. McGranahan N. Bartek J. Swanton C. The causes and consequences of genetic heterogeneity in cancer evolution. Nature 2013 501 7467 338 345 10.1038/nature12625 24048066
    [Google Scholar]
  62. Telekes A. Horváth A. Role of cell-free DNA in cancer treatment decision making 2022 14 6115
    [Google Scholar]
  63. Radvanyi L.G. Bernatchez C. Zhang M. Fox P.S. Miller P. Chacon J. Wu R. Lizee G. Mahoney S. Alvarado G. Glass M. Johnson V.E. McMannis J.D. Shpall E. Prieto V. Papadopoulos N. Kim K. Homsi J. Bedikian A. Hwu W.J. Patel S. Ross M.I. Lee J.E. Gershenwald J.E. Lucci A. Royal R. Cormier J.N. Davies M.A. Mansaray R. Fulbright O.J. Toth C. Ramachandran R. Wardell S. Gonzalez A. Hwu P. Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clin. Cancer Res. 2012 18 24 6758 6770 10.1158/1078‑0432.CCR‑12‑1177 23032743
    [Google Scholar]
  64. Besser M.J. Shapira-Frommer R. Itzhaki O. Treves A.J. Zippel D.B. Levy D. Kubi A. Shoshani N. Zikich D. Ohayon Y. Ohayon D. Shalmon B. Markel G. Yerushalmi R. Apter S. Ben-Nun A. Ben-Ami E. Shimoni A. Nagler A. Schachter J. Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: Intent-to-treat analysis and efficacy after failure to prior immunotherapies. Clin. Cancer Res. 2013 19 17 4792 4800 10.1158/1078‑0432.CCR‑13‑0380 23690483
    [Google Scholar]
  65. Andersen R. Donia M. Ellebaek E. Borch T.H. Kongsted P. Iversen T.Z. Hölmich L.R. Hendel H.W. Met Ö. Andersen M.H. thor Straten P. Svane I.M. Long-lasting complete responses in patients with metastatic melanoma after adoptive cell therapy with tumor-infiltrating lymphocytes and an attenuated IL2 regimen. Clin. Cancer Res. 2016 22 15 3734 3745 10.1158/1078‑0432.CCR‑15‑1879 27006492
    [Google Scholar]
  66. Grigoleit G-U. Kluger H. Thomas S. Chesney J.A. Domingo-Musibay E. Sanmamed M.F. 1086MO Lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy in patients (pts) with advanced mucosal melanoma after progression on immune checkpoint inhibitors (ICI): Results from the phase II C-144-01 study. 2023 34 S654
    [Google Scholar]
  67. Forget M.A. Haymaker C. Hess K.R. Meng Y.J. Creasy C. Karpinets T. Fulbright O.J. Roszik J. Woodman S.E. Kim Y.U. Sakellariou-Thompson D. Bhatta A. Wahl A. Flores E. Thorsen S.T. Tavera R.J. Ramachandran R. Gonzalez A.M. Toth C.L. Wardell S. Mansaray R. Patel V. Carpio D.J. Vaughn C. Farinas C.M. Velasquez P.G. Hwu W.J. Patel S.P. Davies M.A. Diab A. Glitza I.C. Tawbi H. Wong M.K. Cain S. Ross M.I. Lee J.E. Gershenwald J.E. Lucci A. Royal R. Cormier J.N. Wargo J.A. Radvanyi L.G. Torres-Cabala C.A. Beroukhim R. Hwu P. Amaria R.N. Bernatchez C. Prospective analysis of adoptive TIL therapy in patients with metastatic melanoma: response, impact of anti-CTLA4, and biomarkers to predict clinical outcome. Clin. Cancer Res. 2018 24 18 4416 4428 10.1158/1078‑0432.CCR‑17‑3649 29848573
    [Google Scholar]
  68. Neoadjuvant Pembrolizumab and Lenvatinib for Mucosal Melanoma. 2024 Available from: https://clinicaltrials.gov/study/NCT05545969?cond=Mucosal%20Melanoma&limit=100&aggFilters=status:act%20rec%20not&rank=1
  69. Neoadjuvant Treatment Associated With Maintenance Therapy by Anti-PD1 Immunotherapy in Patients With Resectable Head and Neck Mucosal Melanoma. 2024 Available from: https://clinicaltrials.gov/study/NCT03313206?cond=Mucosal%20Melanoma&limit=100&aggFilters=status:act%20rec%20not&rank=7&page=1
  70. Single Arm Study of Induction Chemoradiotherapy Combined With Surgery in the Treatment of Locally Advanced SNMM. 2024 Available from: https://clinicaltrials.gov/study/NCT05009446?cond=Mucosal%20Melanoma&limit=100&aggFilters=status:act%20rec%20not&rank=10&page=1
  71. Postoperative Adjuvant Treatment of Completely Resected Mucosal Melanoma Phase II Study 2024 Available from: https://clinicaltrials.gov/study/NCT04462965?cond=Mucosal%20Melanoma&limit=100&aggFilters=status:act%20rec%20not&rank=4&page=1
  72. Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery 2024 Available from: https://clinicaltrials.gov/study/NCT05111574?cond=Mucosal%20Melanoma&limit=100&aggFilters=status:act%20rec%20not&rank=13&page=1
  73. Toripalimab Combined With Radiotherapy and Chemotherapy in the Treatment of SNMM After Endoscopic Surgery 2024 Available from: https://clinicaltrials.gov/study/NCT04879654?cond=Mucosal%20Melanoma&limit=100&aggFilters=status:act%20rec%20not&rank=20&page=1
  74. Antitumor Activity of Vactosertib in Combination With Pembrolizumab in Acral and Mucosal Melanoma Patients Progressed From Prior Immune Check Point Inhibitor. 2024 Available from: https://clinicaltrials.gov/study/NCT05436990?cond=Mucosal%20Melanoma&limit=100&aggFilters=status:act%20rec%20not&rank=9&page=1
  75. Definition of vactosertib - NCI Drug Dictionary 2011 Available from: https://www.cancer.gov/publications/dictionaries/cancer- drug/def/vactosertib
  76. Coward J. Abed A. Nagrial A. Markman B. Phase I open-label, dose escalation of YH003, an anti-CD40 monoclonal antibody in combination with toripalimab (anti-PD-1 mAb) in patients with advanced solid tumors. JCO 2021 39 2580 2580
    [Google Scholar]
  77. Envafolimab Combined With Recombinant Human Endostatin and First-line Chemotherapy Treat of Advanced Mucosal Melanoma. 2024 Available from: https://clinicaltrials.gov/study/NCT06041724?cond=Mucosal%20Melanoma&limit=100&aggFilters=status:act%20rec%20not&rank=11&page=1
  78. Méndez-Valdés G. Gómez-Hevia F. Lillo-Moya J. González-Fernández T. Abelli J. Cereceda-Cornejo A. Bragato M.C. Saso L. Rodrigo R. Endostatin and cancer therapy: A novel potential alternative to anti-vegf monoclonal antibodies. Biomedicines 2023 11 3 718 10.3390/biomedicines11030718 36979697
    [Google Scholar]
  79. Oral Decitabine/Cedazuridine (DEC-C) in Combination With Nivolumab for Patients With Mucosal Melanoma. 2024 Available from: https://clinicaltrials.gov/study/NCT05089370?cond=Mucosal%20Melanoma&limit=100&aggFilters=status:act%20rec%20not&rank=14&page=1
  80. Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma. Available from: https://clinicaltrials.gov/study/NCT04318717?cond=Mucosal%20Melanoma&limit=100&aggFilters=status:act%20rec%20not&rank=19&page=1
  81. Nemvaleukin Alfa (ALKS 4230) Monotherapy in Patients With Advanced Cutaneous Melanoma or Advanced Mucosal Melanoma - ARTISTRY-6. 2024 Available from: https://clinicaltrials.gov/study/NCT04830124?cond=Mucosal%20Melanoma&limit=100&aggFilters=status:act%20rec%20not&rank=8&page=1
  82. Vaishampayan U.N. Tomczak P. Muzaffar J. Winer I.S. Rosen S.D. Hoimes C.J. Nemvaleukin alfa monotherapy and in combination with pembrolizumab in patients (pts) with advanced solid tumors: ARTISTRY-1. 2022 40 2500 2500
    [Google Scholar]
/content/journals/cpd/10.2174/0113816128340751241220045149
Loading
Mucosal Melanoma: An Overview of Recent Therapies
Bentham Science Publishers ; https://doi.org/10.2174/0113816128340751241220045149
/content/journals/cpd/10.2174/0113816128340751241220045149
/content/journals/cpd/10.2174/0113816128340751241220045149
Loading

Data & Media loading...


  • Article Type:     Review Article
Keywords: exploration of innovative therapies ; evaluation of current treatment methods ; future research directions and prospects ; challenges and limitations ; Mucosal melanoma anti-PD1 Anti-PD1 + Anti-CTL4 adjuvant therapy metastasis TIL therapy background

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test